This is particularly intriguing in the context of the UBE3A fusion gene described above, as it conceivably represents a distinct mechanism of TP53 control in prostate tumors and suggests therapeutic strategies which relieve ubiquitin-mediated TP53 repression may have efficacy [31,32]. Here, UBE3A is linked to prostate neoplasm.